Forget password

We use cookies to help us improve, promote and protect our services. By continuing to use the site, you agree to ourcookie policy

Open
Healthcare & Biomedical

AnBogen Therapeutics

HOME Our Startups
臨床階段生物製藥公司,專注非小細胞肺癌(NSCLC)新藥研究,ABT-101已獲得美國和台灣FDA的研究性新藥(IND)應用批准。

Anbogen Therapeutics (ABT) is a clinical stage biopharmaceutical company founded in 2019, focusing on discovering and developing precision medicine in oncology.